Muller, Marie, Bol, Guus M, Raeisi, Morteza, Malicot, Karine Le, Hegewisch-Becker, Susanna, Fisher, David, Shi, Qian, Chibaudel, Benoist, Koopman, Miriam, Maughan, Tim, Wasan, Harpreet, Arnold, Dirk, Punt, Kees, Phelip, Jean-Marc, Gramont, Aimery de, André, Thierry, Adams, Richard ORCID: https://orcid.org/0000-0003-3915-7243 and Aparicio, Thomas
2026.
Factors associated with chemotherapy free interval (CFI) after induction chemotherapy in metastatic colorectal cancer (mCRC) based on a meta-analysis on ARCAD CRC database: the CFI-SCORE project.
European Journal of Cancer
249
, 118141.
10.1016/j.ejca.2026.118141
|
|
PDF
- Published Version
Available under License Creative Commons Attribution. Download (2MB) |
Abstract
Introduction: After induction therapy, maintenance strategies in metastatic colorectal cancer (mCRC) remain uncertain. Treatment breaks and a chemotherapy-free interval (CFI) may be considered when tumour control is achieved as well as maintenance therapy. Identifying variables of a short/intermediate/long CFI would be useful to guide therapeutic decisions. Materials and methods: CFI-SCORE is an individual patient data meta-analysis assessing clinical and biological factors of short (<3 months), intermediate (3–6 months) or long (≥6–12 months) CFI after induction chemotherapy. Data from 6 international trials comparing observation with continued systemic therapy were pooled. An exploratory score was developed using significant variables. Results: A total of 1188 patients were analysed. Median CFI was 3.67 months; 406 (34.2%), 503 (42.3%), and 279 (23.5%) patients had short, intermediate, and long CFIs, respectively. In multivariable analysis, male sex (adjusted OR [95% CI]: 1.36 [1.04–1.79]), age ≥ 75 years (1.52 [0.99–2.35]), left-sided or rectal primary tumour (1.38 [1.01–1.87]), prior resection of the primary tumour (1.38 [1.06–1.79]), a single metastatic site (1.51 [1.16–1.97]), and absence of thrombocytosis (1.41 [1.00–2.00]) were associated with longer CFI. The exploratory score showed modest discrimination for 6-month CFI prediction (bootstrap-corrected C-statistic, 0.56); the OS C-index was 0.59. Discussion: CFI-SCORE is the first meta-analysis assessing CFI after induction therapy in mCRC. Six parameters were associated with CFI in patients with responding/stable disease and were combined into an exploratory score and nomogram. These results are hypothesis-generating: prospective validation is needed to determine whether CFI-SCORE could guide treatment-break vs maintenance strategies.
| Item Type: | Article |
|---|---|
| Date Type: | Publication |
| Status: | Published |
| Schools: | Schools > Medicine Research Institutes & Centres > Centre for Trials Research (CNTRR) |
| Publisher: | Elsevier |
| ISSN: | 0959-8049 |
| Date of First Compliant Deposit: | 17 November 2026 |
| Date of Acceptance: | 1 November 2026 |
| Last Modified: | 17 Nov 2026 11:45 |
| URI: | https://orca.cardiff.ac.uk/id/eprint/191004 |
Actions (repository staff only)
![]() |
Edit Item |





Dimensions
Dimensions